Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
Palmowski
Moritz
M
Zechmann
Christian
C
Satzl
Stefanie
S
Bartling
Soenke
S
Hallscheidt
Peter
P
D000008:Abdominal Neoplasms / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D016154:Digestive System Fistula / Q000139:chemically induced*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005747:Gastric Fistula / Q000139:chemically induced; D006801:Humans; D016393:Lymphoma, B-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011859:Radiography; D000069283:Rituximab; D013158:Splenic Diseases / Q000139:chemically induced*; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone